[The cytoimmunological effect of concomitant use of sizofiran (SPG) on advanced uterine cervical cancer treated with radiation].
The immunological effect has been studied of the non-specific immunopotentiator sizofiran (SPG) on patients with advanced uterine cervical cancer treated with radiation. Ten cases (study group: SPG group) were administered weekly 40 mg of SPG throughout the course of radiation and two weekly 40 mg during 12 months after radiotherapy. Nineteen cases (control group) were treated with irradiation alone. The lymphocyte count, the PHA index and the ratio of CD4 cells/CD8 cells were significantly reduced by radiotherapy, being observed the most remarkable decrease at post-radiotherapy. But in SPG group, these decreasing values were significantly smaller than in control group and the values showed a more progressive rise during the 12 month respectively. There was no significant difference in peripheral T lymphocyte; CD3, CD4, CD8. The NK cytotoxic activity showed a progressive rise during the 12 month period following a minimal change after radiotherapy. These results suggest that the SPG have some enhancing effect on the function of the lymphocytes.
Iwanari
O
O
Miyako
J
J
Ryuko
K
K
Date
Y
Y
Moriyama
M
M
Moriyama
M
M
Kijima
S
S
Yoshino
N
N
Kitao
M
M
D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D005260:Female; D006025:Glycosaminoglycans / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D012566:Sizofiran / Q000627:therapeutic use*; D014594:Uterine Neoplasms / Q000532:radiotherapy / Q000628:therapy*
D006025:Glycosaminoglycans; D012566:Sizofiran